Management ChangeJul 13, 2026, 04:52 PM
MBX Biosciences Appoints Steven Hoerter as CEO; Kent Hawryluk Departs
AI Summary
MBX Biosciences, Inc. announced a leadership transition, with Kent P. Hawryluk stepping down as Chief Executive Officer and Board member effective July 13, 2026. He will assist with the transition and provide strategic advisory services until August 16, 2026. Concurrently, Steven Hoerter, the company's current Executive Chairman, has been appointed as the new President and Chief Executive Officer, also effective July 13, 2026. Mr. Hoerter's compensation package includes a base salary of $665,000, a target annual bonus of 60%, and significant equity awards.
Key Highlights
- Kent P. Hawryluk will depart as CEO and Board member effective July 13, 2026.
- Dr. Hawryluk will provide strategic advisory services until August 16, 2026, under a consulting agreement.
- Dr. Hawryluk's separation package includes 12 months of base salary severance and COBRA coverage.
- Dr. Hawryluk will receive a cash bonus equal to his target annual bonus.
- Steven Hoerter, current Executive Chairman, is appointed President and CEO effective July 13, 2026.
- Mr. Hoerter's base salary will be $665,000, with a target annual bonus of 60% of his base salary.
- Mr. Hoerter will receive 331,000 stock options and 71,000 restricted stock units (RSUs) on August 3, 2026.
Price Impact
More from MBX